| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Aspergillus fumigatus | 16 | 2025 | 54 | 5.510 |
Why?
|
| Phagosomes | 11 | 2019 | 54 | 3.150 |
Why?
|
| Lectins, C-Type | 11 | 2023 | 89 | 3.090 |
Why?
|
| Physicians | 10 | 2026 | 483 | 2.660 |
Why?
|
| Candida albicans | 14 | 2025 | 74 | 2.520 |
Why?
|
| Macrophages | 15 | 2025 | 1053 | 2.310 |
Why?
|
| Research Personnel | 9 | 2025 | 94 | 2.140 |
Why?
|
| Neutrophils | 10 | 2024 | 378 | 2.010 |
Why?
|
| Candidiasis | 6 | 2024 | 51 | 1.890 |
Why?
|
| Immunity, Innate | 10 | 2025 | 803 | 1.870 |
Why?
|
| Mycoses | 5 | 2025 | 47 | 1.810 |
Why?
|
| Epithelial Cells | 8 | 2025 | 401 | 1.800 |
Why?
|
| Host-Pathogen Interactions | 7 | 2025 | 266 | 1.770 |
Why?
|
| Toll-Like Receptor 9 | 5 | 2019 | 212 | 1.700 |
Why?
|
| beta-Glucans | 6 | 2018 | 56 | 1.660 |
Why?
|
| Kangai-1 Protein | 4 | 2019 | 7 | 1.620 |
Why?
|
| Fungi | 5 | 2025 | 58 | 1.550 |
Why?
|
| Biomedical Research | 8 | 2025 | 270 | 1.500 |
Why?
|
| Aspergillosis | 6 | 2024 | 41 | 1.500 |
Why?
|
| Melanins | 3 | 2025 | 25 | 1.250 |
Why?
|
| Respiratory Mucosa | 2 | 2025 | 56 | 1.140 |
Why?
|
| Optical Tweezers | 3 | 2012 | 8 | 1.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2024 | 616 | 1.080 |
Why?
|
| Staphylococcus aureus | 7 | 2025 | 179 | 1.060 |
Why?
|
| Communicable Diseases | 2 | 2026 | 91 | 1.030 |
Why?
|
| Career Choice | 6 | 2025 | 133 | 1.020 |
Why?
|
| Dendritic Cells | 8 | 2018 | 528 | 1.010 |
Why?
|
| Mice | 41 | 2025 | 11003 | 1.000 |
Why?
|
| Infectious Disease Medicine | 1 | 2026 | 4 | 0.970 |
Why?
|
| Humans | 86 | 2026 | 64238 | 0.960 |
Why?
|
| Animals | 52 | 2025 | 20961 | 0.960 |
Why?
|
| Coccidioides | 1 | 2025 | 11 | 0.940 |
Why?
|
| Reactive Oxygen Species | 4 | 2024 | 237 | 0.940 |
Why?
|
| Chemokine CXCL1 | 1 | 2024 | 6 | 0.870 |
Why?
|
| Single-Cell Analysis | 1 | 2025 | 122 | 0.860 |
Why?
|
| Interleukin-8 | 1 | 2024 | 92 | 0.840 |
Why?
|
| Adenine | 1 | 2024 | 50 | 0.830 |
Why?
|
| Signal Transduction | 12 | 2024 | 3070 | 0.830 |
Why?
|
| Piperidines | 1 | 2024 | 66 | 0.830 |
Why?
|
| Skin Diseases | 1 | 2024 | 83 | 0.810 |
Why?
|
| Dermatology | 1 | 2024 | 75 | 0.800 |
Why?
|
| Cell Wall | 3 | 2020 | 120 | 0.800 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2024 | 161 | 0.780 |
Why?
|
| Internal Medicine | 5 | 2025 | 163 | 0.780 |
Why?
|
| Mannans | 1 | 2023 | 20 | 0.770 |
Why?
|
| Phagocytosis | 11 | 2024 | 266 | 0.770 |
Why?
|
| Anaplasmosis | 1 | 2022 | 5 | 0.740 |
Why?
|
| Anaplasma phagocytophilum | 1 | 2022 | 9 | 0.730 |
Why?
|
| Cell Nucleus | 2 | 2019 | 632 | 0.730 |
Why?
|
| Interferon Type I | 1 | 2024 | 187 | 0.720 |
Why?
|
| Spores, Fungal | 4 | 2020 | 20 | 0.720 |
Why?
|
| Cell Line | 16 | 2020 | 2055 | 0.710 |
Why?
|
| Bias | 1 | 2022 | 114 | 0.700 |
Why?
|
| Microscopy | 2 | 2012 | 94 | 0.680 |
Why?
|
| Staphylococcal Infections | 5 | 2025 | 130 | 0.680 |
Why?
|
| Education, Medical | 2 | 2020 | 185 | 0.670 |
Why?
|
| Calcium | 1 | 2024 | 580 | 0.670 |
Why?
|
| Quality of Life | 3 | 2024 | 1257 | 0.630 |
Why?
|
| Internship and Residency | 6 | 2024 | 808 | 0.620 |
Why?
|
| Microscopy, Confocal | 6 | 2016 | 239 | 0.620 |
Why?
|
| Cryptococcus neoformans | 6 | 2025 | 148 | 0.610 |
Why?
|
| Pneumothorax | 1 | 2019 | 50 | 0.600 |
Why?
|
| Oligodeoxyribonucleotides | 2 | 2019 | 244 | 0.580 |
Why?
|
| Vaping | 1 | 2019 | 44 | 0.580 |
Why?
|
| Histocompatibility Antigens Class II | 3 | 2008 | 182 | 0.570 |
Why?
|
| Anti-Bacterial Agents | 7 | 2026 | 800 | 0.570 |
Why?
|
| Decision Making | 1 | 2022 | 416 | 0.560 |
Why?
|
| Cytokines | 8 | 2025 | 944 | 0.560 |
Why?
|
| Saccharomyces cerevisiae | 3 | 2025 | 567 | 0.540 |
Why?
|
| CARD Signaling Adaptor Proteins | 4 | 2024 | 70 | 0.540 |
Why?
|
| Cell Membrane | 3 | 2019 | 501 | 0.530 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2016 | 113 | 0.520 |
Why?
|
| Ascomycota | 1 | 2017 | 12 | 0.520 |
Why?
|
| Histocompatibility Antigens Class I | 6 | 2008 | 145 | 0.510 |
Why?
|
| Lentivirus | 1 | 2016 | 67 | 0.490 |
Why?
|
| Syk Kinase | 4 | 2020 | 9 | 0.490 |
Why?
|
| Adaptive Immunity | 2 | 2018 | 103 | 0.490 |
Why?
|
| Immunomodulation | 2 | 2025 | 32 | 0.460 |
Why?
|
| Virus Shedding | 3 | 2025 | 20 | 0.430 |
Why?
|
| Protein Transport | 5 | 2016 | 405 | 0.430 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2025 | 108 | 0.420 |
Why?
|
| Bacterial Proteins | 7 | 2025 | 775 | 0.420 |
Why?
|
| Health Personnel | 2 | 2022 | 389 | 0.410 |
Why?
|
| Occupational Exposure | 1 | 2016 | 315 | 0.410 |
Why?
|
| West Nile Fever | 1 | 2013 | 5 | 0.400 |
Why?
|
| Meningoencephalitis | 1 | 2013 | 8 | 0.400 |
Why?
|
| Lateral Ventricles | 1 | 2013 | 7 | 0.400 |
Why?
|
| Mice, Inbred C57BL | 10 | 2025 | 3450 | 0.390 |
Why?
|
| Mice, Knockout | 8 | 2019 | 2140 | 0.390 |
Why?
|
| Cryptococcosis | 3 | 2011 | 79 | 0.390 |
Why?
|
| Lysosomes | 4 | 2014 | 169 | 0.390 |
Why?
|
| Inflammation | 5 | 2024 | 1162 | 0.380 |
Why?
|
| Candida | 2 | 2023 | 41 | 0.360 |
Why?
|
| Lung | 5 | 2024 | 964 | 0.360 |
Why?
|
| Antiviral Agents | 2 | 2025 | 329 | 0.360 |
Why?
|
| Aspergillus | 1 | 2011 | 12 | 0.350 |
Why?
|
| Immunocompromised Host | 2 | 2012 | 108 | 0.340 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2011 | 10 | 0.340 |
Why?
|
| Cells, Cultured | 7 | 2025 | 2176 | 0.340 |
Why?
|
| Models, Immunological | 1 | 2010 | 86 | 0.330 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 1019 | 0.330 |
Why?
|
| Genetic Vectors | 1 | 2016 | 889 | 0.330 |
Why?
|
| Ritonavir | 3 | 2025 | 19 | 0.330 |
Why?
|
| Immunologic Factors | 2 | 2025 | 109 | 0.320 |
Why?
|
| Escherichia coli Infections | 1 | 2010 | 89 | 0.320 |
Why?
|
| Awards and Prizes | 3 | 2025 | 34 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2016 | 128 | 0.310 |
Why?
|
| Antigen Presentation | 3 | 2018 | 241 | 0.300 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2025 | 209 | 0.300 |
Why?
|
| Gene Expression Regulation | 4 | 2020 | 1621 | 0.290 |
Why?
|
| Antigens, CD | 2 | 2007 | 348 | 0.290 |
Why?
|
| Gene Expression Profiling | 3 | 2025 | 783 | 0.290 |
Why?
|
| Diagnosis, Differential | 4 | 2022 | 984 | 0.280 |
Why?
|
| Fever | 2 | 2022 | 66 | 0.280 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2016 | 343 | 0.280 |
Why?
|
| Proguanil | 1 | 2007 | 6 | 0.280 |
Why?
|
| Atovaquone | 1 | 2007 | 5 | 0.280 |
Why?
|
| Babesia microti | 1 | 2007 | 7 | 0.280 |
Why?
|
| Babesiosis | 1 | 2007 | 12 | 0.280 |
Why?
|
| Membrane Proteins | 4 | 2011 | 909 | 0.270 |
Why?
|
| Thinking | 2 | 2018 | 29 | 0.270 |
Why?
|
| Societies, Medical | 3 | 2018 | 381 | 0.270 |
Why?
|
| Antifungal Agents | 5 | 2024 | 128 | 0.270 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2007 | 137 | 0.260 |
Why?
|
| Actinomycosis | 1 | 2006 | 5 | 0.260 |
Why?
|
| Abdominal Abscess | 1 | 2006 | 13 | 0.260 |
Why?
|
| Acids | 1 | 2006 | 14 | 0.250 |
Why?
|
| H-2 Antigens | 4 | 1995 | 67 | 0.250 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2006 | 50 | 0.250 |
Why?
|
| Endosomes | 1 | 2007 | 178 | 0.240 |
Why?
|
| Alanine | 2 | 2024 | 51 | 0.240 |
Why?
|
| Microtubules | 1 | 2007 | 210 | 0.240 |
Why?
|
| Antigens, Surface | 1 | 2006 | 199 | 0.240 |
Why?
|
| Coccidioidomycosis | 1 | 2025 | 12 | 0.240 |
Why?
|
| Autophagy | 4 | 2016 | 231 | 0.230 |
Why?
|
| Interleukin-1beta | 2 | 2019 | 271 | 0.230 |
Why?
|
| Pseudomonas Infections | 1 | 2025 | 54 | 0.230 |
Why?
|
| Respiratory Tract Infections | 1 | 2025 | 90 | 0.220 |
Why?
|
| Career Mobility | 1 | 2025 | 64 | 0.220 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 46 | 0.220 |
Why?
|
| Phenazines | 1 | 2024 | 10 | 0.220 |
Why?
|
| Leukocyte Elastase | 1 | 2024 | 14 | 0.220 |
Why?
|
| Adenosine Monophosphate | 1 | 2024 | 30 | 0.220 |
Why?
|
| Models, Biological | 3 | 2016 | 1187 | 0.210 |
Why?
|
| Streptococcus pneumoniae | 1 | 2024 | 66 | 0.210 |
Why?
|
| Endocytosis | 1 | 2025 | 153 | 0.210 |
Why?
|
| Training Support | 3 | 2018 | 22 | 0.210 |
Why?
|
| Cystic Fibrosis | 1 | 2025 | 124 | 0.210 |
Why?
|
| Membrane Transport Proteins | 3 | 2024 | 136 | 0.210 |
Why?
|
| Chemokines | 1 | 2024 | 93 | 0.210 |
Why?
|
| NADPH Oxidases | 2 | 2014 | 70 | 0.200 |
Why?
|
| Benchmarking | 1 | 2024 | 134 | 0.200 |
Why?
|
| Pyrazoles | 1 | 2024 | 87 | 0.200 |
Why?
|
| Bacteremia | 1 | 2024 | 94 | 0.200 |
Why?
|
| Immunotherapy | 1 | 2026 | 265 | 0.200 |
Why?
|
| Education, Medical, Graduate | 2 | 2024 | 350 | 0.200 |
Why?
|
| Membrane Glycoproteins | 1 | 2006 | 671 | 0.200 |
Why?
|
| Pyrimidines | 1 | 2024 | 146 | 0.200 |
Why?
|
| Job Syndrome | 1 | 2023 | 3 | 0.200 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 63 | 0.200 |
Why?
|
| Galactose | 1 | 2023 | 13 | 0.200 |
Why?
|
| Drug Resistance, Viral | 1 | 2024 | 156 | 0.190 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 189 | 0.190 |
Why?
|
| SAIDS Vaccines | 1 | 2022 | 22 | 0.190 |
Why?
|
| Virus Cultivation | 1 | 2022 | 19 | 0.190 |
Why?
|
| Hydrogen-Ion Concentration | 3 | 2016 | 462 | 0.190 |
Why?
|
| Psychometrics | 1 | 2024 | 385 | 0.190 |
Why?
|
| Myalgia | 1 | 2022 | 2 | 0.190 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2022 | 23 | 0.190 |
Why?
|
| AIDS Vaccines | 1 | 2022 | 72 | 0.180 |
Why?
|
| Ciprofloxacin | 1 | 2021 | 26 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2022 | 49 | 0.180 |
Why?
|
| Monocytes | 2 | 2014 | 356 | 0.180 |
Why?
|
| Diarrhea | 1 | 2022 | 76 | 0.180 |
Why?
|
| Papillomavirus Vaccines | 1 | 2022 | 70 | 0.180 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 101 | 0.170 |
Why?
|
| Mammals | 1 | 2023 | 219 | 0.170 |
Why?
|
| Interleukin-6 | 2 | 2014 | 324 | 0.170 |
Why?
|
| Peptides | 3 | 1994 | 590 | 0.170 |
Why?
|
| O Antigens | 1 | 2020 | 5 | 0.170 |
Why?
|
| Cholera | 1 | 2020 | 14 | 0.170 |
Why?
|
| Vibrio cholerae | 1 | 2020 | 18 | 0.170 |
Why?
|
| Virus Replication | 1 | 2022 | 323 | 0.160 |
Why?
|
| Transcriptome | 1 | 2023 | 396 | 0.160 |
Why?
|
| Naphthols | 1 | 2020 | 4 | 0.160 |
Why?
|
| Cough | 1 | 2022 | 182 | 0.160 |
Why?
|
| Surgery, Plastic | 1 | 2020 | 19 | 0.160 |
Why?
|
| Retinopathy of Prematurity | 1 | 2000 | 14 | 0.160 |
Why?
|
| Male | 13 | 2025 | 30294 | 0.160 |
Why?
|
| TRPV Cation Channels | 1 | 2020 | 21 | 0.160 |
Why?
|
| Nobel Prize | 1 | 2020 | 14 | 0.160 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 24 | 0.160 |
Why?
|
| NF-kappa B | 2 | 2019 | 471 | 0.160 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 42 | 0.160 |
Why?
|
| Reproducibility of Results | 1 | 2024 | 1681 | 0.160 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2000 | 39 | 0.160 |
Why?
|
| Antibodies, Bacterial | 1 | 2020 | 182 | 0.160 |
Why?
|
| Chest Tubes | 1 | 2019 | 17 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2019 | 727 | 0.150 |
Why?
|
| Patient Care | 1 | 2020 | 79 | 0.150 |
Why?
|
| Endoplasmic Reticulum | 2 | 2019 | 175 | 0.150 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 55 | 0.150 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 120 | 0.150 |
Why?
|
| Immunity, Cellular | 2 | 2019 | 178 | 0.150 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2019 | 114 | 0.150 |
Why?
|
| Middle Aged | 7 | 2025 | 17898 | 0.150 |
Why?
|
| Membrane Microdomains | 1 | 2019 | 50 | 0.150 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 870 | 0.150 |
Why?
|
| Salmonella typhimurium | 2 | 2012 | 86 | 0.140 |
Why?
|
| Flow Cytometry | 5 | 2016 | 668 | 0.140 |
Why?
|
| Drainage | 1 | 2019 | 155 | 0.140 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 6 | 0.140 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 429 | 0.140 |
Why?
|
| Gene Knockout Techniques | 2 | 2016 | 96 | 0.140 |
Why?
|
| Education | 1 | 2018 | 69 | 0.140 |
Why?
|
| Hematology | 1 | 2018 | 12 | 0.140 |
Why?
|
| Pathogen-Associated Molecular Pattern Molecules | 1 | 2018 | 5 | 0.140 |
Why?
|
| Phagocytes | 1 | 2018 | 52 | 0.140 |
Why?
|
| National Institutes of Health (U.S.) | 3 | 2025 | 119 | 0.140 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 1494 | 0.140 |
Why?
|
| N-Formylmethionine | 2 | 2000 | 3 | 0.140 |
Why?
|
| Recurrence | 1 | 2019 | 650 | 0.130 |
Why?
|
| Phosphorylation | 2 | 2024 | 948 | 0.130 |
Why?
|
| Tetraspanin 30 | 2 | 2007 | 2 | 0.130 |
Why?
|
| Platelet Membrane Glycoproteins | 2 | 2007 | 5 | 0.130 |
Why?
|
| Hyphae | 1 | 2017 | 18 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.130 |
Why?
|
| CD36 Antigens | 1 | 2017 | 27 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Carbohydrates | 1 | 2017 | 40 | 0.130 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 219 | 0.130 |
Why?
|
| Female | 11 | 2025 | 33350 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 497 | 0.120 |
Why?
|
| Integrin alphaV | 1 | 2016 | 2 | 0.120 |
Why?
|
| Protein Kinase C-delta | 1 | 2016 | 8 | 0.120 |
Why?
|
| Mucormycosis | 1 | 2016 | 10 | 0.120 |
Why?
|
| Psoriasis | 1 | 2016 | 58 | 0.120 |
Why?
|
| Point-of-Care Testing | 1 | 2016 | 42 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 437 | 0.120 |
Why?
|
| Thrombosis | 1 | 2018 | 198 | 0.120 |
Why?
|
| N-Formylmethionine Leucyl-Phenylalanine | 1 | 2015 | 19 | 0.120 |
Why?
|
| Biological Assay | 1 | 2016 | 58 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 2015 | 26 | 0.120 |
Why?
|
| Receptors, Mitogen | 1 | 2015 | 7 | 0.120 |
Why?
|
| Drug Delivery Systems | 1 | 2019 | 329 | 0.120 |
Why?
|
| Hydrocephalus | 1 | 2016 | 43 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 181 | 0.110 |
Why?
|
| Bone Marrow Cells | 3 | 2020 | 237 | 0.110 |
Why?
|
| Asthma | 1 | 2020 | 471 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2016 | 263 | 0.110 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.110 |
Why?
|
| Salmonella Infections | 1 | 2015 | 42 | 0.110 |
Why?
|
| Brain Diseases | 1 | 2016 | 78 | 0.110 |
Why?
|
| United States | 6 | 2025 | 7923 | 0.110 |
Why?
|
| Macrophages, Alveolar | 2 | 2013 | 64 | 0.110 |
Why?
|
| Occupational Health | 1 | 2016 | 187 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 2 | 2017 | 223 | 0.110 |
Why?
|
| Interleukin-1 | 1 | 2015 | 156 | 0.110 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 178 | 0.110 |
Why?
|
| Vitamin A | 1 | 2014 | 28 | 0.110 |
Why?
|
| Cross Infection | 1 | 2016 | 167 | 0.110 |
Why?
|
| Candida glabrata | 1 | 2014 | 2 | 0.110 |
Why?
|
| Proteoglycans | 1 | 2014 | 32 | 0.110 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 2238 | 0.110 |
Why?
|
| Ubiquitin | 2 | 2012 | 106 | 0.100 |
Why?
|
| Chimera | 1 | 1994 | 42 | 0.100 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 433 | 0.100 |
Why?
|
| Crohn Disease | 1 | 2015 | 110 | 0.100 |
Why?
|
| Lactams | 2 | 2023 | 24 | 0.100 |
Why?
|
| West Nile virus | 1 | 2013 | 7 | 0.100 |
Why?
|
| Confusion | 1 | 2013 | 17 | 0.100 |
Why?
|
| rab5 GTP-Binding Proteins | 1 | 2013 | 22 | 0.100 |
Why?
|
| Proline | 2 | 2023 | 49 | 0.100 |
Why?
|
| Escherichia coli | 2 | 2010 | 718 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 1995 | 417 | 0.100 |
Why?
|
| Nitriles | 2 | 2023 | 79 | 0.100 |
Why?
|
| Leucine | 2 | 2023 | 67 | 0.100 |
Why?
|
| B-Lymphocytes | 1 | 2016 | 571 | 0.100 |
Why?
|
| Encephalitis | 1 | 2013 | 36 | 0.100 |
Why?
|
| HeLa Cells | 2 | 2012 | 540 | 0.100 |
Why?
|
| Aged | 5 | 2025 | 14648 | 0.100 |
Why?
|
| Alcoholism | 1 | 2016 | 323 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 788 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2017 | 728 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2013 | 386 | 0.090 |
Why?
|
| Prospective Studies | 3 | 2025 | 3315 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 402 | 0.090 |
Why?
|
| Cellulases | 1 | 2011 | 1 | 0.090 |
Why?
|
| Fusariosis | 1 | 2011 | 3 | 0.090 |
Why?
|
| Microspheres | 1 | 2011 | 57 | 0.090 |
Why?
|
| Fusarium | 1 | 2011 | 9 | 0.090 |
Why?
|
| Adolescent | 3 | 2019 | 6304 | 0.090 |
Why?
|
| Moths | 1 | 2011 | 27 | 0.090 |
Why?
|
| Adult | 8 | 2025 | 17116 | 0.090 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 136 | 0.090 |
Why?
|
| Radiography | 1 | 2013 | 552 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2023 | 1365 | 0.090 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 147 | 0.090 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2012 | 224 | 0.080 |
Why?
|
| Surface Properties | 1 | 2011 | 281 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2010 | 65 | 0.080 |
Why?
|
| Jurkat Cells | 1 | 2010 | 110 | 0.080 |
Why?
|
| Mutation | 3 | 2024 | 2629 | 0.080 |
Why?
|
| Carrier Proteins | 1 | 2015 | 709 | 0.080 |
Why?
|
| Tetracycline | 2 | 2024 | 24 | 0.080 |
Why?
|
| Intracellular Membranes | 1 | 2010 | 50 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 128 | 0.080 |
Why?
|
| Staining and Labeling | 1 | 2011 | 126 | 0.080 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 234 | 0.080 |
Why?
|
| Cell Communication | 1 | 2010 | 132 | 0.080 |
Why?
|
| Hypertension | 2 | 2013 | 593 | 0.080 |
Why?
|
| Antigen-Presenting Cells | 1 | 2010 | 178 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2000 | 182 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2016 | 2046 | 0.080 |
Why?
|
| Time Factors | 4 | 2024 | 3724 | 0.080 |
Why?
|
| Molecular Sequence Data | 6 | 1995 | 1997 | 0.080 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2024 | 166 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2010 | 351 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2012 | 677 | 0.070 |
Why?
|
| Genes, Reporter | 2 | 2006 | 260 | 0.070 |
Why?
|
| HEK293 Cells | 1 | 2010 | 627 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2011 | 329 | 0.070 |
Why?
|
| Living Donors | 1 | 2008 | 78 | 0.070 |
Why?
|
| Gene Expression | 1 | 2011 | 851 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 495 | 0.070 |
Why?
|
| Lysosomal-Associated Membrane Protein 1 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Nocodazole | 1 | 2007 | 15 | 0.070 |
Why?
|
| Drug Combinations | 1 | 2007 | 168 | 0.070 |
Why?
|
| Polymers | 1 | 2010 | 327 | 0.070 |
Why?
|
| Brain | 1 | 2016 | 1581 | 0.070 |
Why?
|
| Cell Compartmentation | 1 | 2007 | 36 | 0.070 |
Why?
|
| Methylmercury Compounds | 1 | 2007 | 1 | 0.070 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 2737 | 0.060 |
Why?
|
| Actinomyces | 1 | 2006 | 3 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2011 | 483 | 0.060 |
Why?
|
| Membrane Fusion | 1 | 2006 | 68 | 0.060 |
Why?
|
| Lung Diseases, Fungal | 1 | 2006 | 35 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2006 | 34 | 0.060 |
Why?
|
| Microbial Viability | 2 | 2017 | 56 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2024 | 2604 | 0.060 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2006 | 55 | 0.060 |
Why?
|
| Environmental Monitoring | 1 | 2007 | 149 | 0.060 |
Why?
|
| Kidney | 1 | 2008 | 455 | 0.060 |
Why?
|
| Lab-On-A-Chip Devices | 2 | 2016 | 24 | 0.060 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 132 | 0.060 |
Why?
|
| Sputum | 1 | 2025 | 43 | 0.060 |
Why?
|
| Virulence Factors | 1 | 2025 | 85 | 0.060 |
Why?
|
| Salmonella Infections, Animal | 1 | 2005 | 10 | 0.060 |
Why?
|
| Receptors, Chemokine | 1 | 2005 | 33 | 0.060 |
Why?
|
| Amino Acid Sequence | 5 | 1995 | 1597 | 0.060 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 268 | 0.060 |
Why?
|
| Coinfection | 1 | 2025 | 58 | 0.050 |
Why?
|
| Immunity, Mucosal | 1 | 2005 | 52 | 0.050 |
Why?
|
| Streptolysins | 1 | 2024 | 10 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 463 | 0.050 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2024 | 14 | 0.050 |
Why?
|
| Species Specificity | 1 | 2025 | 334 | 0.050 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2024 | 22 | 0.050 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2024 | 28 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2006 | 283 | 0.050 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 624 | 0.050 |
Why?
|
| Nafcillin | 1 | 2024 | 2 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2024 | 12 | 0.050 |
Why?
|
| Oxacillin | 1 | 2024 | 5 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2004 | 19 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2025 | 275 | 0.050 |
Why?
|
| Viral Load | 1 | 2025 | 233 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2006 | 259 | 0.050 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2024 | 58 | 0.050 |
Why?
|
| Education, Graduate | 1 | 2023 | 17 | 0.050 |
Why?
|
| Respiratory System | 1 | 2023 | 48 | 0.050 |
Why?
|
| Kinetics | 2 | 2024 | 766 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2025 | 313 | 0.050 |
Why?
|
| Protein Binding | 4 | 2017 | 1618 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2025 | 272 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2023 | 116 | 0.050 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2022 | 4 | 0.050 |
Why?
|
| England | 2 | 2000 | 30 | 0.050 |
Why?
|
| Convalescence | 1 | 2022 | 18 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2005 | 243 | 0.050 |
Why?
|
| Immunity | 1 | 2023 | 107 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2022 | 51 | 0.050 |
Why?
|
| Cell Lineage | 1 | 2023 | 273 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 127 | 0.050 |
Why?
|
| STAT3 Transcription Factor | 1 | 2023 | 72 | 0.050 |
Why?
|
| Vero Cells | 1 | 2022 | 81 | 0.050 |
Why?
|
| Mupirocin | 1 | 2021 | 3 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2021 | 19 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1272 | 0.040 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 116 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 410 | 0.040 |
Why?
|
| Virulence | 2 | 2011 | 195 | 0.040 |
Why?
|
| Animals, Suckling | 1 | 2020 | 2 | 0.040 |
Why?
|
| Agglutination | 1 | 2020 | 5 | 0.040 |
Why?
|
| Biomarkers | 1 | 2006 | 1431 | 0.040 |
Why?
|
| Bangladesh | 1 | 2020 | 25 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 107 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 214 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 329 | 0.040 |
Why?
|
| Survival Rate | 2 | 2000 | 859 | 0.040 |
Why?
|
| Cosmetic Techniques | 1 | 2020 | 12 | 0.040 |
Why?
|
| Bronchioles | 1 | 2020 | 5 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2024 | 555 | 0.040 |
Why?
|
| Return to Work | 1 | 2020 | 26 | 0.040 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 147 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2020 | 37 | 0.040 |
Why?
|
| Allergens | 1 | 2020 | 58 | 0.040 |
Why?
|
| Extracellular Traps | 1 | 2020 | 44 | 0.040 |
Why?
|
| Calcineurin | 1 | 2020 | 47 | 0.040 |
Why?
|
| Vaccines, Synthetic | 1 | 2000 | 78 | 0.040 |
Why?
|
| Calcium Channels | 1 | 2020 | 103 | 0.040 |
Why?
|
| Immunization | 1 | 2000 | 135 | 0.040 |
Why?
|
| Risk Factors | 3 | 2020 | 5339 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 371 | 0.040 |
Why?
|
| Gestational Age | 1 | 2000 | 191 | 0.040 |
Why?
|
| Bacterial Vaccines | 1 | 2000 | 81 | 0.040 |
Why?
|
| Charities | 1 | 2018 | 3 | 0.040 |
Why?
|
| Foundations | 1 | 2018 | 9 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2000 | 498 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2020 | 164 | 0.040 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2018 | 2 | 0.040 |
Why?
|
| Immunological Synapses | 1 | 2018 | 10 | 0.040 |
Why?
|
| Microscopy, Atomic Force | 1 | 2018 | 32 | 0.030 |
Why?
|
| Incidence | 1 | 2022 | 1383 | 0.030 |
Why?
|
| Perforin | 1 | 2018 | 31 | 0.030 |
Why?
|
| Cytoplasmic Granules | 1 | 2018 | 53 | 0.030 |
Why?
|
| In Vitro Techniques | 2 | 2016 | 490 | 0.030 |
Why?
|
| Solubility | 1 | 2018 | 189 | 0.030 |
Why?
|
| Cell Polarity | 1 | 2018 | 109 | 0.030 |
Why?
|
| Mentors | 1 | 2018 | 122 | 0.030 |
Why?
|
| Centralized Hospital Services | 1 | 1997 | 6 | 0.030 |
Why?
|
| Medical History Taking | 1 | 2017 | 68 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 52 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2018 | 158 | 0.030 |
Why?
|
| Physical Examination | 1 | 2017 | 111 | 0.030 |
Why?
|
| Chloroquine | 1 | 2017 | 61 | 0.030 |
Why?
|
| Ligands | 1 | 2018 | 417 | 0.030 |
Why?
|
| Health Policy | 1 | 2018 | 195 | 0.030 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2016 | 10 | 0.030 |
Why?
|
| Mucorales | 1 | 2016 | 1 | 0.030 |
Why?
|
| Integrin beta3 | 1 | 2016 | 9 | 0.030 |
Why?
|
| Cerebrospinal Fluid Shunts | 1 | 2016 | 10 | 0.030 |
Why?
|
| Consciousness Disorders | 1 | 2016 | 10 | 0.030 |
Why?
|
| Macrophage-1 Antigen | 1 | 2016 | 30 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2013 | 1297 | 0.030 |
Why?
|
| Zebrafish | 1 | 2019 | 350 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2018 | 704 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 125 | 0.030 |
Why?
|
| Students, Medical | 1 | 2018 | 268 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2000 | 1375 | 0.030 |
Why?
|
| NADH Dehydrogenase | 1 | 1995 | 5 | 0.030 |
Why?
|
| Autophagy-Related Proteins | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2000 | 416 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2016 | 174 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 1993 | 374 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 458 | 0.030 |
Why?
|
| Salmonella | 1 | 2015 | 44 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1561 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2016 | 614 | 0.030 |
Why?
|
| Child | 2 | 2022 | 4583 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 132 | 0.030 |
Why?
|
| Intracellular Space | 1 | 2014 | 35 | 0.030 |
Why?
|
| Alleles | 1 | 2015 | 448 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 119 | 0.030 |
Why?
|
| Nucleoproteins | 1 | 1993 | 34 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2016 | 5691 | 0.030 |
Why?
|
| Zymosan | 1 | 2013 | 25 | 0.020 |
Why?
|
| Critical Care | 1 | 1997 | 402 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 482 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 1992 | 70 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2005 | 375 | 0.020 |
Why?
|
| Glycine | 1 | 1992 | 50 | 0.020 |
Why?
|
| Motion | 1 | 1992 | 62 | 0.020 |
Why?
|
| Temperature | 1 | 1994 | 312 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 685 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 726 | 0.020 |
Why?
|
| Genomics | 1 | 2015 | 379 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2016 | 1001 | 0.020 |
Why?
|
| Base Sequence | 1 | 1994 | 1332 | 0.020 |
Why?
|
| Larva | 1 | 2011 | 145 | 0.020 |
Why?
|
| Acute Disease | 1 | 2013 | 672 | 0.020 |
Why?
|
| Oligopeptides | 1 | 1991 | 135 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2012 | 674 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2010 | 43 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2010 | 40 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 46 | 0.020 |
Why?
|
| HIV Infections | 1 | 2018 | 976 | 0.020 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2010 | 25 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 152 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 319 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 231 | 0.020 |
Why?
|
| Proteinuria | 1 | 2008 | 43 | 0.020 |
Why?
|
| Albuminuria | 1 | 2008 | 31 | 0.020 |
Why?
|
| Mitochondria | 1 | 1991 | 384 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 1669 | 0.020 |
Why?
|
| Nephrectomy | 1 | 2008 | 92 | 0.020 |
Why?
|
| Developing Countries | 1 | 2008 | 94 | 0.020 |
Why?
|
| Social Behavior | 1 | 2008 | 89 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2000 | 6726 | 0.020 |
Why?
|
| Phenotype | 1 | 2011 | 1222 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2007 | 53 | 0.020 |
Why?
|
| Prognosis | 1 | 2011 | 1769 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 2217 | 0.020 |
Why?
|
| Hair | 1 | 2007 | 83 | 0.020 |
Why?
|
| Cricetinae | 1 | 2006 | 368 | 0.010 |
Why?
|
| Health Status | 1 | 2008 | 447 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 460 | 0.010 |
Why?
|
| Mental Health | 1 | 2008 | 372 | 0.010 |
Why?
|
| Chemokines, CX3C | 1 | 2005 | 4 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 4776 | 0.010 |
Why?
|
| Chemokine CX3CL1 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 297 | 0.010 |
Why?
|
| Ileum | 1 | 2005 | 21 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 207 | 0.010 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2005 | 13 | 0.010 |
Why?
|
| Lymphoid Tissue | 1 | 2005 | 55 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 544 | 0.010 |
Why?
|
| Peyer's Patches | 1 | 2005 | 35 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2006 | 329 | 0.010 |
Why?
|
| Intestine, Small | 1 | 2005 | 80 | 0.010 |
Why?
|
| Hydrazones | 1 | 2004 | 5 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2004 | 31 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2004 | 77 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 68 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 901 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2004 | 130 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2004 | 206 | 0.010 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 88 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2005 | 312 | 0.010 |
Why?
|
| Catalysis | 1 | 2004 | 164 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2004 | 136 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 97 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 140 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 534 | 0.010 |
Why?
|
| Cytosol | 1 | 2004 | 181 | 0.010 |
Why?
|
| Rats | 1 | 2006 | 2005 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 2478 | 0.010 |
Why?
|
| Formates | 2 | 1993 | 2 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2006 | 512 | 0.010 |
Why?
|
| Protein Folding | 1 | 2004 | 268 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 266 | 0.010 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 443 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1551 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 2000 | 98 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 2000 | 59 | 0.010 |
Why?
|
| Pregnancy | 1 | 2007 | 2370 | 0.010 |
Why?
|
| Victoria | 1 | 1997 | 7 | 0.010 |
Why?
|
| Mortality | 1 | 1997 | 161 | 0.010 |
Why?
|
| Patient Admission | 1 | 1997 | 198 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1997 | 203 | 0.010 |
Why?
|
| Odds Ratio | 1 | 1997 | 759 | 0.010 |
Why?
|
| HLA-G Antigens | 1 | 1994 | 1 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1994 | 63 | 0.010 |
Why?
|
| Parainfluenza Virus 1, Human | 1 | 1993 | 3 | 0.010 |
Why?
|
| Logistic Models | 1 | 1997 | 1270 | 0.010 |
Why?
|
| Alkylation | 1 | 1993 | 15 | 0.010 |
Why?
|
| Vesicular stomatitis Indiana virus | 1 | 1993 | 17 | 0.010 |
Why?
|
| Nucleocapsid Proteins | 1 | 1993 | 36 | 0.010 |
Why?
|
| Viral Core Proteins | 1 | 1993 | 30 | 0.010 |
Why?
|
| Length of Stay | 1 | 1997 | 818 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1993 | 116 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1993 | 137 | 0.010 |
Why?
|
| Infant | 1 | 1997 | 1664 | 0.010 |
Why?
|
| Epitopes | 1 | 1993 | 292 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1997 | 2018 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1991 | 192 | 0.010 |
Why?
|